Bjarne Gram Hansen

Title: Bjarne Gram Hansen: Innovator in Coagulation Research

Introduction

Bjarne Gram Hansen is a notable inventor based in Alleroed, Denmark. He has made significant contributions to the field of coagulation research, particularly in the development of procoagulant antibodies. With a total of 2 patents, his work has the potential to impact the treatment of coagulopathies such as hemophilia A.

Latest Patents

Bjarne's latest patents focus on improved procoagulant antibodies. The first patent describes bispecific antibodies capable of binding to coagulation Factor IX (FIX) or its activated form, Factor IXa (FIXa), and optionally Factor X (FX) and its activated form, Factor Xa (FXa). These antibodies promote FX activation by FIXa and provide methods and compositions for treating subjects suffering from coagulopathy. The second patent relates to multispecific procoagulant antibodies that bind to FIX and/or FIXa, as well as FX and/or FXa, promoting FX activation by FIXa. This patent also includes methods and compositions for treating coagulopathy and outlines kits and methods of manufacture.

Career Highlights

Bjarne Gram Hansen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to focus on innovative solutions in the field of coagulation.

Collaborations

Bjarne collaborates with talented coworkers, including Karina Thorn and Laust Bruun Johnsen. Their combined expertise contributes to the advancement of research and development in coagulation therapies.

Conclusion

Bjarne Gram Hansen's contributions to the field of coagulation research through his innovative patents and collaborations highlight his role as a significant inventor. His work has the potential to improve treatment options for individuals suffering from coagulopathies.